Company news

IDEAYA Biosciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer

June 24, 2024

IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors

June 23, 2024

IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study

June 2, 2024

IDEAYA Biosciences to Participate in Upcoming June 2024 Investor Relations Events

May 28, 2024

IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business Development

May 27, 2024

IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

May 6, 2024

IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event

April 30, 2024

IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study

April 23, 2024

IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer

April 21, 2024

IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event

March 31, 2024

IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer

March 11, 2024

IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events

March 3, 2024

IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

February 19, 2024

IDEAYA Biosciences to Participate in Upcoming February 2024 Investor Relations Events

January 31, 2024

IDEAYA Biosciences Announces Participation at the 42nd Annual J.P. Morgan Healthcare Conference and 2024 Corporate Guidance

January 6, 2024

IDEAYA Biosciences to Participate in Upcoming December 2023 Investor Relations Event

December 4, 2023

IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy® and IDE397 Combination in MTAP-Deletion Bladder Cancer

December 3, 2023

IDEAYA Announces Agenda for Investor R&D Day Webcast on December 4, 2023

December 2, 2023

IDEAYA Biosciences, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update

November 6, 2023

IDEAYA Biosciences Announces Plans for Investor R&D Day and Participation in Jefferies London Healthcare Conference

October 31, 2023

IDEAYA Announces Top-Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ/11 Cutaneous Melanoma, and Synthetic Lethality Pipeline

October 22, 2023

IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2023 for Phase 2 Clinical Data Update for Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma

October 16, 2023

IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ/11 Metastatic Cutaneous Melanoma

October 15, 2023

IDEAYA Biosciences Announces Development Candidate Nomination of a Werner Helicase Inhibitor in Collaboration with GSK and Investor R&D Day

October 8, 2023

IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, Her2-, BRCA1/2 mutant Breast Cancer

September 26, 2023

IDEAYA Receives Fast Track Designation for Potential First-in-Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum-Resistant Advanced or Metastatic Ovarian Cancer Patients having tumors with BRCA1/2 Mutations

September 25, 2023

IDEAYA Announces Phase 1 Expansion and Preliminary Clinical Proof-of-Concept for Potential First-in-Class PARG Inhibitor IDE161 in HRD Solid Tumors

September 10, 2023

IDEAYA Biosciences to Participate in Upcoming September 2023 Investor Relations Events

September 4, 2023

IDEAYA Biosciences Announces Clearance of IND Application for Pol Theta Helicase Development Candidate GSK101 (IDE705)

August 20, 2023

IDEAYA Announces First-Patient-In for Company-Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in (Neo)Adjuvant Uveal Melanoma

August 15, 2023

IDEAYA Biosciences, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update

August 9, 2023

IDEAYA and Amgen Achieve First-Patient-In for Clinical Evaluation of IDE397 (MAT2A) and AMG 193 (PRMT5(MTA)) Combination in MTAP(-/-) Tumors

August 1, 2023

IDEAYA Biosciences to Participate in Upcoming August 2023 Investor Relations Event

July 31, 2023

IDEAYA Announces First Reported Case of Uveal Melanoma Patient Spared Enucleation in Phase 1 Neoadjuvant IST with Darovasertib Monotherapy

June 21, 2023

IDEAYA Announces Selection of IDE397 Phase 2 Monotherapy Expansion Dose For Global Enrollment Targeting High Priority MTAP-Deletion Solid Tumor Types

June 11, 2023

IDEAYA Biosciences to Participate in Upcoming June 2023 Investor Relations Events

May 29, 2023

IDEAYA Announces IND Clearance Enabling Phase 1/2 Clinical Trial for Combination of IDE397 and AMG 193 in MTAP-Deletion Solid Tumors

May 21, 2023

IDEAYA Expands Clinical Trial Collaboration and Supply Agreements with Pfizer to Support Registrational Trial Evaluating Darovasertib and Crizotinib Combination in First-Line Metastatic Uveal Melanoma

May 15, 2023

IDEAYA Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

May 8, 2023

IDEAYA Biosciences to Participate in Upcoming May 2023 Investor Relations Event

April 30, 2023

IDEAYA Announces Proposed Public Offering of Common Stock

April 23, 2023

IDEAYA Announces Positive Interim Phase 2 Data for Darovasertib and Crizotinib Combination and Successful FDA Type C Meeting on Registrational Trial Design for Accelerated Approval in First-Line Metastatic Uveal Melanoma

April 22, 2023

IDEAYA Announces First Patient Dosed in Phase 1 Clinical Trial for IDE161 as Potential First-in-Class PARG Inhibitor Targeting HRD Solid Tumors

April 18, 2023

IDEAYA Biosciences to Participate in Upcoming April 2023 Investor Relations Event

April 2, 2023

IDEAYA Announces Presentations at AACR Annual Meeting 2023 for Potential First-in-Class Synthetic Lethality Programs IDE397 (MAT2A), IDE161 (PARG) and Werner Helicase

March 13, 2023

IDEAYA Biosciences, Inc. Reports 2022 Financial Results and Provides Business Update

March 6, 2023

IDEAYA Biosciences to Participate in Investor Conferences in March 2023

February 28, 2023

IDEAYA Biosciences to Participate in Citi's 2023 Virtual Oncology Leadership Summit

February 15, 2023

IDEAYA Biosciences to Participate in the 2023 Guggenheim Oncology Conference

January 31, 2023

IDEAYA Announces Darovasertib Phase 2 Initiation in Neoadjuvant and Adjuvant Uveal Melanoma and Guidance for Clinical Data Update in Metastatic Uveal Melanoma

January 22, 2023

← Newer news releases · Older news releases →

Decks

The 5 newest of 23 decks. Every deck is listed under its year.